Hi Scientist, it's Lisa from the Policy Team. At the American Society of Clinical Oncology (ASCO) Annual Meeting in June, results were presented from the phase III clinical trial OlympiAD, which compared olaparib to standard chemotherapy for women with a BRCA gene mutation who had developed metastatic HER2-negative breast cancer. The researchers found that olaparib was generally well tolerated, with the most common side effects being nausea and anaemia (lack of red blood cells). The study found that 4.9% of women in the study discontinued olaparib due to side effects compared to 7.7% of women who were treated with chemotherapy. You may have discussed the side effects of olaparib with your medical oncologist already, but just in case not, your oncologist will be able to give you the best information about possible side effects you might experience.
Warm regards,
Lisa
